Anti-COVID drug DRDO gets emergency use of DCGI

New Delhi: India’s Comptroller General of Medicines has approved an oral anti-COVID drug, developed by DRDO, for emergency use as an adjunct to patients with moderate to severe coronavirus, the Ministry of Health said on Saturday. Defense.

He said clinical trials of the drug 2-deoxy-D-glucose (2-DG) have shown that it helps in faster recovery in hospital patients and reduces dependence on supplemental oxygen.

The drug was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of the Defense Research and Development Organization (DRDO), in collaboration with Dr Reddy’s laboratories at Hyderabad.

2-DG comes in the form of a powder in a sachet and is taken orally by dissolving it in water.

Also Read: VINS Bioproducts Bags DCGI to Begin VINCOV-19 Trials

On May 1, the DCGI authorized the emergency use of this drug as an adjunct in patients with moderate to severe COVID-19. Being a generic molecule and a glucose analogue, it can be easily produced and made available in abundance in the country, ”the ministry said in a statement.

“It accumulates in cells infected with the virus and prevents the growth of the virus by stopping viral synthesis and energy production. Its selective accumulation in cells infected with the virus makes this drug unique, ”the ministry said.

Source link

About Catherine Sherrill

Check Also

Global Study Report on Single-Use Medical Device Reprocessing Market 2021-2028 | Stryker Corporation, Medline ReNewal, Centurion Medical Products Corporation

The concept of sterilizing, packaging, testing and producing a used product is known as single …

Leave a Reply

Your email address will not be published. Required fields are marked *